Breast Cancer
📧 Sign up to get email alerts when something new happens for Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database
A completed real-world database study sponsored by Pfizer aims to characterize patients with advanced or metastatic breast cancer who are tr…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon） [Phase 3]
A Phase 3 study called Cinnamon is evaluating whether intensifying treatment with CDK4/6 inhibitors can omit chemotherapy in small-sized, hi…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Endoscopic Nipple-Sparing Mastectomy Through a Single Axillary Incision in Breast Cancer [NA]
An ongoing clinical trial is evaluating endoscopic nipple-sparing mastectomy through a single axillary incision for breast cancer, including…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer [Phase 2]
Phase 2 clinical trial exploring dalpiciclib with or without entinostat and letrozole for HR+/HER2- early breast cancer, currently recruitin…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Screening Mammography: Single Reading by One Radiologist With AI vs. Double Reading by Two Radiologists (AI-BCSQ) [NA]
Clinical trial comparing single-reading by one radiologist with AI versus double-reading by two radiologists for breast cancer screening; cu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype [Phase 2]
A Phase 2 trial comparing trastuzumab deruxtecan versus CDK4/6 inhibitor–based endocrine therapy as first-line treatment for HR-positive, HE…
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation [Phase 3]
Phase 3 clinical trial evaluating alpelisib in combination with trastuzumab and pertuzumab as maintenance therapy for HER2-positive advanced…
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Roll-over Study to Allow Continued Access to Ribociclib [Phase 4]
A Phase 4 roll-over study provides continued access to ribociclib for patients with metastatic breast cancer.
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer [Phase 2]
Phase 2 trial exploring concurrent neoadjuvant chemotherapy and endocrine therapy for HER2-positive breast cancer; the study is currently no…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer [NA]
An ongoing SWOG trial (S1703) is evaluating serum tumor marker-directed disease monitoring in hormone receptor-positive, HER2-negative metas…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) [Phase 3]
A Phase 3 study of Sacituzumab Tirumotecan (MK-2870) as a single agent and in combination with pembrolizumab (MK-3475) versus physician's ch…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China
A registry-like real-world study in China evaluating first-line treatment patterns and outcomes for HR+/HER2- advanced or metastatic breast …
-
CLINICAL_TRIALS other · 2026-04-02Clinical Trial Update: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer [Phase 2]
A single-arm Phase II trial evaluating adjuvant endocrine therapy combined with pertuzumab and trastuzumab in patients with anatomic stage I…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance [Phase 4]
A Phase 4 clinical trial update describes evaluating a dose-frequency escalation strategy for an endocrine therapy in breast cancer and its …
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer [Phase 1]
Regor Pharmaceuticals is conducting a Phase 1 trial of RGT-419B alone and in combination with endocrine therapy for HR-positive, HER2-negati…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II [NA]
A clinical trial evaluating stereotactic ablative body radiotherapy with maintenance systemic therapy versus physician's choice of systemic …
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) [Phase 1]
First-in-human, dose-escalation Phase 1 study of a dendritic cell vaccine (DCV) is underway, with recruitment for leptomeningeal carcinomato…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Classification of Breast Masses Based on Visco-elastic Properties Using SAVE Method
A Mayo Clinic study evaluating classification of breast masses by visco-elastic properties using the SAVE method has completed. The trial in…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer [Phase 1]
Phase 1 clinical trial evaluating adoptive T cell therapy after a HER2-pulsed dendritic cell vaccine, in combination with pepinemab and tras…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile [Phase 2]
Phase 2 trial evaluating a personalized antiemetic regimen guided by patients' pharmacogenetic profile in breast cancer.
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Motivating to Exercise and Diet, and Educating to Healthy Behaviors After Breast Cancer [NA]
A completed clinical trial tested strategies to motivate overweight or obese breast cancer patients to exercise, follow a healthier diet, an…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Evaluation of EnVisio SmartClip for Intraoperative Localization of Breast Masses
Clinical trial evaluating the EnVisio SmartClip for locating breast masses in surgery has completed.
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Clinical Breast Examination and Patient Navigation Intervention in Sub-Saharan Africa [NA]
This entry reports an active-but-not-recruiting clinical trial from Addis Ababa University evaluating clinical breast examination and patien…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer [Phase 4]
This Phase 4 study assesses the pharmacokinetic model of abemaciclib and its correlation with severe diarrhea as the primary toxicity endpoi…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
This is a non-interventional study evaluating the use of ribociclib (Kisqali) in combination with an aromatase inhibitor as adjuvant therapy…